December 12, 2007 - UCB announced that the supplemental New Drug Application (sNDA) for the use of Neupro as a treatment for moderate-to-severe restless legs syndrome (RLS) has been accepted for filing by the U.S. Food and Drug Administration (FDA)...Restless Legs Syndrome is a chronic neurological disorder that affects between three and ten per cent of the population...Symptoms of RLS typically appear during periods of rest and inactivity, particularly in the evenings and at night. This can make it difficult to fall asleep and stay asleep, thus preventing recuperative sleep and often leading to daytime fatigue and reduced alertness... UCB's Press Release -
Thursday, December 27, 2007
UCB's Neupro, Filed with the FDA for the Treatment of Restless Legs Syndrome
December 12, 2007 - UCB announced that the supplemental New Drug Application (sNDA) for the use of Neupro as a treatment for moderate-to-severe restless legs syndrome (RLS) has been accepted for filing by the U.S. Food and Drug Administration (FDA)...Restless Legs Syndrome is a chronic neurological disorder that affects between three and ten per cent of the population...Symptoms of RLS typically appear during periods of rest and inactivity, particularly in the evenings and at night. This can make it difficult to fall asleep and stay asleep, thus preventing recuperative sleep and often leading to daytime fatigue and reduced alertness... UCB's Press Release -
